Glaukos Corp (GKOS) FinancialsGKOSGlaukos Corp

Glaukos Corporation (GKOS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Glaucoma, accounting for 83.6% of total sales, equivalent to $155.18M. Another important revenue stream is Corneal Health. Understanding this composition is critical for investors evaluating how GKOS navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Glaukos Corporation maintains a gross margin of 81.67%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8.49%, while the net margin is -9.90%. These profitability ratios, combined with a Return on Equity (ROE) of -25.98%, provide a clear picture of how effectively GKOS converts its operational activities into shareholder value.

In the context of the broader market, GKOS competes directly with industry leaders such as BIO and GMED. With a market capitalization of $10.73B, it holds a significant position in the sector. When comparing efficiency, GKOS's gross margin of 81.67% stands against BIO's 53.12% and GMED's 65.68%. Such benchmarking helps identify whether Glaukos Corporation is trading at a premium or discount relative to its financial performance.

Glaukos reported Q2 2026 revenue of $185.6 million, a 50% increase year-over-year, but continues to incur net losses, with a net income of -$18.4 million.